For research and educational purposes only. Not medical advice.
ARA-290 Reference
Educational, not medical advice reference for ARA-290: Recovery, Immune, Longevity; regulatory status, evidence posture, source review, and schedule notes. A…
Reference summary
Preclinical studies report tissue-protective, anti-inflammatory, and neuropathic-pain signals; clinical programs remain investigational and indication-specific.
- Categories
- Recovery, Immune, Longevity
- Aliases
- Cibinetide, pHBSP, Pyroglutamate helix B surface peptide
- Evidence posture
- translational — Investigational EPO-derived peptide. Human community use for neuropathy, inflammation, or longevity is not validated by an approved product or broad outcome program.
- Regulatory status
- No FDA-approved ARA-290 / cibinetide drug label. ClinicalTrials.gov lists investigational studies, including sarcoidosis-associated small-fiber neuropathy. It is not approved for neuropathy, autoimmune disease, longevity, or recovery use.
- Content review status
- research reference